NDAORALCONCENTRATE
Approved
Apr 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PERMITIL (fluphenazine hydrochloride) by Merck & Co. is clinical pharmacology fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. Approved for the management of manifestations of psychotic disorders. First approved in 1965.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERMITIL (fluphenazine hydrochloride) is an oral antipsychotic concentrate approved in 1965 for managing manifestations of psychotic disorders. The drug exerts activity across multiple CNS levels and organ systems, though its exact therapeutic mechanism remains unknown. It represents a first-generation antipsychotic with established clinical utility in schizophrenia and related conditions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating potential team consolidation and shift toward generic optimization or adjacent indications.
Mechanism of Action
CLINICAL PHARMACOLOGY Fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. The mechanism whereby its therapeutic action is exerted is unknown.
Indications (1)
Career Relevance
PERMITIL offers limited career development opportunities given its LOE-approaching status and zero linked job openings. Roles on this product typically focus on managing decline, optimizing margins on generic conversions, and maintaining formulary access rather than growth initiatives.
Worked on PERMITIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.